Strongest evidence
The highest-confidence finding is for increased 25-hydroxyvitamin D levels (high evidence strength, 6 of 6 studies beneficial, mixed effect sizes). Moderate-strength evidence supports improvements in insulin sensitivity (5 of 6 studies beneficial, mixed effect sizes), reduced HOMA-IR (3 of 4 meta-analyses beneficial, small effects), reduced C-reactive protein (3 of 4 studies, moderate effects), and improved quality of life (4 of 4 studies, predominantly small effects). Doses across these moderate-strength outcomes were inconsistently reported but included 4000 IU/day and 60,000 IU/week where available.
Mixed or weaker evidence
Low-strength evidence is available for six outcomes, with mostly neutral or inconsistent results. Reduced inflammation in autoimmune arthritis populations showed small beneficial effects in all 4 studies, but the evidence base is small. Outcomes like reduced blood cholesterol, fasting blood glucose, BMI, triglycerides, LDL cholesterol, and systolic blood pressure each had 1-2 beneficial studies out of 3-4 total, with the majority showing neutral effects. The beneficial findings were often limited to specific clinical subgroups (e.g., MAFLD patients, obese youths with deficiency), limiting generalizability.
Effective dose patterns
No consistent effective dose emerged across outcomes. Where reported, daily doses ranged from 240 to 4000 IU/day, and weekly doses up to 50,000 IU. Most studies did not specify the form of vitamin D, though two syntheses noted that vitamin D2 (ergocalciferol) may differ from D3 (cholecalciferol) in efficacy for HOMA-IR and CRP reduction.
Population insights
Beneficial effects were most consistently observed in individuals with low baseline vitamin D levels (deficiency or insufficiency) and in clinical populations (diabetes, prediabetes, PCOS, MAFLD, autoimmune conditions). Effects in generally healthy or non-deficient populations were often neutral or smaller. Obese children and adolescents frequently showed neutral results across multiple metabolic outcomes.
Notable caveats
Publication bias is a recurring caveat — null-result studies may be under-indexed, especially for outcomes where all studies report benefit. The evidence base is small for most outcomes (3-6 studies each), and many syntheses note that co-supplementation with other nutrients (magnesium, vitamin E, Salacia reticulata) complicates attribution of effects to vitamin D alone. Dose and form reporting was inconsistent across studies, limiting practical dose-response conclusions.